Comparative palatability of five supplements designed for cats suffering from chronic renal disease by Natalia Bernachon et al.
Iris Tréidliachta Éireann
Bernachon et al. Irish Veterinary Journal 2014, 67:10
http://www.irishvetjournal.org/content/67/1/10RESEARCH Open AccessComparative palatability of five supplements
designed for cats suffering from chronic renal
disease
Natalia Bernachon1*, Sandrine Fournel2, Hugues Gatto3, Patricia Monginoux3 and David McGahie1Abstract
Background: Intestinal phosphate binders, uremic toxin binders and some other types of supplements are an integral
part of the management of chronic kidney disease (CKD) in various species, including cats. This pathology in domestic
carnivores requires life-long nutritional and medical management. In this context, the compliance of owners and patients
cannot be achieved without an adequate level of palatability for oral medication or supplementation. Knowing that
hyporexia and anorexia are among the most commonly seen clinical signs in cats suffering from CKD this is already, in
itself, a serious obstacle to acceptable compliance in sick animals. The aim of the present study was to investigate the
palatability of four commercially available products designed for cats suffering from CKD: Ipakitine® (Vetoquinol, France),
Azodyl® (Vetoquinol, USA), Renalzin® (Bayer, France), Rubenal® (Vetoquinol, France) and an additional recently developed
product: Pronefra® (Virbac, France). The study was performed with a group of previously-characterised cats, all living in an
enriched and well-being securing environment of an independent centre housing panels of pets expert in palatability
measurement. In total 172 monadic testings were performed. The palatability of each product was assessed by measuring
their rates of prehension and consumption, and the consumption proportions were also analysed.
Results: The most palatable presentation (based on useful consumption) was Pronefra®, which was significantly higher
than Azodyl® (p = 0.046), Ipakitine® (p < 0.0001), Renalzin® (p < 0.0001) and Rubenal® (p < 0.0001). The product with the
highest rate of prehension was also Pronefra®, which was significantly higher than Azodyl® (p = 0.0019), Ipakitine®
(p = 0.0023), Renalzin® (p = 0.0008) and Rubenal® (p < 0.0001).
Conclusion: Pronefra® was the most palatable presentation tested, meaning it may be useful for improving ease of
supplementation in CKD cats.
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Chronic kidney disease (CKD) is one of the most common
pathological conditions seen in domestic carnivores, espe-
cially elderly cats. This disease is known to affect more than
30% of cats over 10 years of age [1], and the mean age for
diagnosis is reported to be close to 13 years [2]. It has been
recognised that nutritional intervention plays a vital role in
the management of many diseases in aging cats and has a
special role in the management of renal disorders [3].
Currently, several oral supplements are marketed with* Correspondence: natalia.bernachon@virbac.com
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article, unless otherwise stated.proposed benefits for multiple aspects of renal disease in-
cluding intestinal phosphate binders (IPB), uremic toxin
binders, agents intended to reduce progression of fibrotic
changes, antioxidants and vitamin supplements. Unfortu-
nately, these products are intended for use in a group of an-
imals already well-known to have poor compliance [4] and
none of the existing products appear to respond to the
practical need to have one supplement associating several
aspects of nutritional management in a highly palatable and
easy-to-give form.
Three main targets can be seen in current nutritional
management of CKD cats: restriction of available dietary
phosphorus, reducing absorption of uremic toxins and re-
duction of the progression of fibrotic changes. Managementtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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CKD patient because anorexia, hyporexia, nausea and
vomiting are common and prominent signs of uremia [5].
The benefits of simultaneous use of chitosan and phosphate
binders to reduce intestinal ammonia absorption in cats
have been shown previously [6] and are an accepted part of
the dietary management of CKD in the dog [7].
Glomerulosclerosis, tubulointerstitial lesions, inflamma-
tion and fibrosis are common findings in CKD and seem to
be independent from the initiating factor of the disease [5].
Some natural agents have shown encouraging results and
appear to be efficient in reducing renal inflammation and fi-
brosis in laboratory animals and humans [8,9], thus justify-
ing use of such supplements in domestic carnivores.
However, of all recommended management options
for CKD the current consensus is that restriction of
available dietary phosphorus is the major contributor in
slowing the disease progression and improving survival
times [6,10-14]. The regulation of serum phosphorus
concentrations in the body is dependent on the balance
between dietary intake of phosphorus and its excretion
rate [15]. The kidneys have a pivotal role in the regula-
tion of phosphorus levels because they are the first and
the main route of phosphorus excretion in cats [5]. Even
if dietary intake remains stable, the decline in the glom-
erular filtration rate (GFR) in animals with CKD will be
translated into hyperphosphatemia and result in an acti-
vation of compensatory mechanisms such as secondary
hyperparathyroidism which are often deleterious for the
kidney itself. Secondary hyperparathyroidism can be
seen even in the early stages of CKD in domestic carni-
vores where ionized calcium and serum phosphorus
concentrations often remain within normal ranges
[5,10,16,17]. Probably these “normal-range” phosphorus
levels are slightly higher than physiologically normal for
the individual cat (despite being within the laboratory
reference ranges) and/or are maintained only through
constantly high levels of PTH [12].
Thus management of the dietary availability of phos-
phorus in patients suffering from chronic renal disease
and/or hyperparathyroidism could be useful from the early
stages [10]. Where possible this should be based on accur-
ate monitoring, tailored to the individual cat [12].
The majority of dietary phosphorus comes from protein-
rich ingredients in the diet [12,18,19]. Three options are
currently available for the management of dietary phos-
phorus availability in CKD patients [19]: change to a diet
specially restricted in phosphorus and/or in protein, use of
IPB or both of these in combination. However, the loss of
lean body mass is one of the factors associated with pro-
gressive CKD in cats [13] and is due to impaired absorption
of nutrients from the digestive tract, reduced appetite, nau-
sea, vomiting and malnutrition related to disease progres-
sion. It has been reported to be associated with shortersurvival [2] and even to be predictive of clinical deterior-
ation in CKD patients [20]. Beyond the scope of CKD, a
large proportion of elderly cats, more than 9 years of age,
have a tendency to lose body weight due to impaired diges-
tion of proteins [3]. Thus in most cases maintenance of the
dietary protein intake (and the proportion of energy ob-
tained from dietary protein) may be required to help main-
tain lean body mass (LBM) in aging cats [3]. It has been
reported that the addition of IPB to a diet with a normal
protein content is often sufficient to control phosphate
levels in cats in IRIS stage 2 CKD [10] Thus, phosphate re-
striction with simultaneous maintenance of the standard
protein level seems to be preferable in the early stages of
CKD [19]. Progressive loss of the functional ability of the
kidneys will progressively require a shift to a low phos-
phorus renal diet and, if necessary, also IPB in the later
stages of the disease [10].
Despite the fact that there is scientific evidence for the
benefits of IPB [10,12,15,21] a recent survey in the
United States performed in 1080 cats has shown that the
majority of cats (78,8%) with CKD are not receiving a
phosphorus binding agent [22]. Market research studies
in Europe show that IPB are prescribed only in 41% of
CKD patients (in both dogs and cats) [23]. Practitioners
report a lack of palatability of some supplements [5] and
the galenic forms are not always well adapted to cats
resulting in poor compliance. This problem is even more
in evidence when there is a need to provide multiple
products to manage multiple aspects of the disease. Pal-
atability has been cited as one of the major factors that
influence the selection of a phosphate-binding agent
given the fact that in cats presented with azotemia their
appetite is often variable or may be selective for certain
foods [5]. For this reason the palatability of products de-
signed specifically for CKD cats should be of primary
importance in order to avoid inappetence due to the na-
ture of the product.
The goal of this study was to assess, in a panel of stan-
dardised cats, the comparative palatability of the avail-
able supplements for cats with CKD along with an
additional supplement that was in the late stages of de-
velopment at the time.
Methods
Animal selection and test procedure
The study was done with a group of previously-
characterised cats, all living in the enriched and well-
being securing environment of an independent centre
housing panels of pets expert in palatability measure-
ment. This study was carried out in accordance with the
relevant European legislation and Virbac’s chart of
Ethics.
A total of one hundred and seventy two individual ap-
petite assessments were made in 5 groups of male and
Bernachon et al. Irish Veterinary Journal 2014, 67:10 Page 3 of 7
http://www.irishvetjournal.org/content/67/1/10female adult cats to test the palatability of 5 oral supple-
ments. All products were administered 3 hours after the
morning meal. Powder, liquid and paste supplements
were given with 5 g of kibble to provide a base for the
products. The key characteristics (age, gender, weight,
normal appetite levels) of all 5 groups were similar on
the test day (Table 1). The cats were housed in stable
small groups, but were placed in individual boxes for the
purposes of the test.
Coupled with thorough statistical analyses, the observa-
tions recorded were designed to establish the acceptability
and consumption of each supplement. Video records were
obtained to allow independent assessment without interfer-
ing with the cat’s behaviour. Each animal was offered
its allocated test product in its box during 10 minutes.
Consumption and prehension were assessed as described
below.
Consumption was classified using four categories:
 Ingestion of >95% of the product was defined as
total consumption.
 Ingestion of 50-95% of the product was defined as
good partial consumption.
 Ingestion of ≥10% but <50% of the product was
defined poor partial consumption.
 Ingestion of <10% of the product was defined as a
refusal to consume the product.
Ingestion of ≥50% (total plus good partial consump-



























Rubenal® 31 4 3.87
9 females
555 sterilised females
17 neutered malesconsumption. This was therefore defined as useful
consumption.
Prehension was defined as the animal voluntarily tak-
ing the product in the mouth, whether or not it was
then subsequently consumed.
Tested products
The five tested products (see Table 2 for details) were:
Azodyl®, (Vetoquinol, USA), Ipakitine®, (Vetoquinol,
France), Pronefra®, (Virbac, France), Renalzin®, (Bayer,
France), Rubenal®, (Vetoquinol, France). The tested
products were commercially available batches bought
through veterinary wholesalers for the four existing
products. The new product (Pronefra®) was supplied by
the manufacturer. Three products contained IPB (Ipaki-
tine®, Pronefra®, Renalzin®), three products contained in-
testinal N-binders (Azodyl®, Ipakitine®, Pronefra®), two
products contained natural agents thought to contribute
to the maintenance of normal kidney architecture (Pro-
nefra®, Rubenal®).
Statistical analysis
Statistical analyses were performed using SAS 9.3. The
parameters prehension, total consumption and useful
consumption (as defined above) were compared be-
tween groups using a binomial model with group as
fixed factor.
In case of significant group effect, pair-wise comparisons
were performed between each pair of groups (Likelihood
ratio or Wald chi square test).





to 70 g 2
Premium or Super premium kibbles
(High diversity)
to 70 g 2
Premium or Super premium kibbles
(High diversity)
to 70 g 2
Premium or Super premium kibbles
(High diversity)
to 70 g 2
Premium or Super premium kibbles
(High diversity)
to 70 g 2
Premium or Super premium kibbles
(High diversity)
Table 2 Product characteristics and administration method used
Name Content Galenic form Manufacturer’s guidelines Administration
method used
Azodyl Bacterial products: (Kibow Biotics®: E. thermophilus
(KB 19), L. acidophilus (KB 27), B. longum (KB 31))
Powder in single
dose capsules
1 to 3 capsules daily depending
on weight
One capsule of powder
spread over 5 g of kibble
Psyllium husk
Ipakitine -IPB (calcium carbonate) Powder One spoon of powder (1 g) per
5 kg of BW, spread on the food
One spoon of powder
spread on 5 g of kibble
-Chitosan








-Hydrolysate of fish protein
Renalzin -IPB (lanthanum carbonate) Paste Two presses (~2 ml) per cat, spread
on the food
One press of paste spread
on 5 g of kibble
Rubena75 -Rheum officinale, extract Tablet 2 tablets per cat daily 1 tablet placed in the bowl
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product for the following parameters:
 Prehension
 Total consumption
 Useful consumption (total plus good partial
consumption).
Results
The percentage of prehension noted in each group is
displayed in Figure 1. When statistical analysis of the
prehension rate was performed, two distinct groups
were noted. Group A was composed of Pronefra®, and
group B was composed of Azodyl®, Ipakitine®, Renalzin®
and Rubenal®. Spontaneous prehension of the only
product in group A (Pronefra®) was found to be statisti-
cally superior to each of the products in group B. No
statistical difference in spontaneous prehension was
found between any of the products in group B. See
Table 3 and Figure 1 for details.Figure 1 Prehension of CKD supplements in cats. This chart
presents the level of spontaneous prehension for the tested
products and demonstrates two statistically different groups, A and
B. Columns not bearing a similar letter are significantly different.Total consumption data is displayed in Figure 2. When
statistical analysis of total consumption was performed, four
distinct groups were noted. The groups were named such
that groups which were statistically different did not contain
a common letter. Specifically: Group A was composed of
Pronefra®, group AB was composed of Azodyl®, group CB
was composed of Rubenal®, and group C was composed of
Ipakitine® and Renalzin® The level of total consumption was
found to be statistically superior for statistical group A
when compared to groups CB and C. Group AB was also
superior to group C. No statistical difference was found be-
tween groups A and AB, between groups AB and BC, or be-
tween groups BC and C. See Table 3 and Figure 2 for details.
Useful consumption data (defined as ingestion of ≥50%)
are presented in Figure 3. When statistical analysis of
useful consumption was performed, four distinct groups
were noted. Group A was composed of Pronefra®, group
B was composed of Azodyl®, group C was composed of
Rubenal® and Renalzin® and group D was composed of
Ipakitine®. The level of useful consumption was found
to be statistically superior for statistical group A (product
Pronefra®) when compared to all other groups (B, C and
D). Group D (product Ipakitine®) was found to be statisti-
cally inferior to all other groups (A, B and C) (see Table 3
and Figure 3 for details). Data relating to refusal to con-
sume supplements is presented in Table 3 and Figure 4.
Discussion
One objective of this study design was to model the situ-
ation of cats in the early stages of the disease or cats
with strong food preferences where IPB are added to
food with a normal protein content. In fact, as the dis-
ease progresses in cats they become more and more
anorexic [4] and unwilling to accept new flavours. This
means that it is desirable to introduce any supplements
at an early stage after diagnosis of CKD, ideally without
Table 3 P-values for the pairwise comparisons of the level of prehension, total consumption, useful consumption and
refusal for each product
Product comparisons Prehension Total consumption Useful consumption Refusal
Ipakitine vs Renalzin 0.6293 1.0000 0.0005* 0.3383
Ipakitine vs Azodyl 0.9207 0.0011* <.0001* 0.7038
Ipakitine vs Rubenal 0.1450 0.0786 0.0118* 0.0076
Ipakitine vs Pronefra 0.0023* <.0001* <.0001* <.0001*
Renalzin vs Azodil 0.7039 0.0011* 0.0336* 0.1838
Renalzin vs Rubenal 0.3176 0.0786 0.2906 0.0784
Renalzin vs Pronefra 0.0008* <.0001* <.0001* <.0001*
Azodyl vs Rubenal 0.1758 0.0900 0.0022* 0.0026*
Azodyl vs Pronefra 0.0019* 0.1088 0.0459* 0.0002*
Rubenal vs Pronefra <.0001* 0.0013* <.0001* <.0001*
Where products are significantly different, this is noted in bold with an asterisk.
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This is particularly the case for IPBs, where it has been
shown that they can be efficient even before obvious
hyperphosphatemia is identified [11,12,19,21].
It is possible that healthy cats are not well representative
of the differences between product palatabilty in sick cats.
This is a major limitation of the study. However, use of
healthy cats avoids the large variability in appetite levels
seen in sick cats, avoids the ethical problems seen when
testing products in cats which are already stabilised on ap-
propriate management options and avoids the risks of
interference due to previous exposure to the products.
It could be interesting to attempt to follow the products
in the field as a prospective study, but this would require
very large numbers of cats to provide meaningful results.
For the four existing presentations (Azodyl®, Ipakitine®,
Renalzin® and Rubenal®) prehension was shown to be ra-
ther low in healthy cats. Voluntary prehension is not al-
ways easy to achieve in cats, but is clearly the first
requirement in cases where the owner is unwilling or
unable to use a forced administration for the animal.Figure 2 Total consumption of CKD supplements in cats. The
bars indicate the percentage of cats which consumed more than
95% of the product in each group. Columns not bearing a similar
letter are significantly different.Tablet presentations are often more adapted to forced
administration unless they are highly palatable.
For the total consumption data, the statistical analysis
revealed more complexity with four overlapping groups
(Figure 2 and Table 3); despite this complexity the most
clear contrast revealed was within the products contain-
ing IPB. As noted previously, the most important goal
for nutritional management of cats with CKD is the re-
duction of serum phosphorus which has been shown to
correlate with extended lifespan [10-15]. We did not see
extremely high proportions of cats willing to consume
the product totally for any product containing IPB.
However, the fact that no cats were willing to totally
consume the product for the two IPB-containing supple-
ments in group C (Ipakitine® and Renalzin®) is potentially
a concern. The significantly higher result for Pronefra®
may represent an important benefit in the compliance of
cats requiring IPB administration. As seen with prehen-
sion data, no statistical difference was noted between the
two products not containing IPB.
Cats are well known to be a species inclined to neo-
phobia [24], and more specifically cats with CKD areFigure 3 Useful consumption of CKD supplements in cats. The
bars indicate the percentage of cats which consumed more than
50% of the product in each group. Columns not bearing a similar
letter are significantly different.
Figure 4 Refusal to consume CKD supplements in cats. The bars
indicate the percentage of cats which consumed less than 10% of
the product in each group. Columns not bearing a similar letter are
significantly different.
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obtain 100% consumption of a newly introduced product is
difficult and a consumption rate that exceeds 50-70% of the
product could be a desirable target. It could also be reason-
ably argued that at least 50% of the recommended amount
may be assumed to be necessary to provide obvious benefit
for the animal. For this reason we defined consumption as
useful when more than 50% of the delivered product was
willingly consumed by the cat. In contrast, consumption
not exceeding 10% was defined as refusal given the fact that
it is unreasonable to expect any real benefit from a product
consumed at this rate.
The useful consumption statistical analyses once again
demonstrated the existence of a distinct difference among
the products containing IPB. Once again Pronefra® stood
out as being distinctly separated from Renalzin® and Ipaki-
tine®. However in this analysis around one quarter of the
cats were willing to consume amounts of Renalzin® that
were defined as useful. Once again, and somewhat surpris-
ingly, no cats were willing to consume useful amounts of
Ipakitine®. This low innate palatability combined with its
galenic presentation as a powder which makes forced
administration extremely difficult will almost certainly
compromise compliance. For the analysis of useful
consumption, the situation for the products not containing
an IPB was different to that for total consumption and pre-
hension: Azodyl® was found to be statistically superior to
Rubenal® and was consumed to a useful level by around half
of the cats.
The difference between products containing an IPB
appears to be even more pronounced when refusal to
consume is assessed with around half of all cats refusing
to consume the two previously existing products.
The products in this study were administered with dry
food. It is possible that use of canned foods may have
produced a different result due to the inherent palatabil-
ity of the wet food which may be used to mask to low
palatability of the supplements. However the purpose of
this study was to assess the inherent palatability of the
supplements in isolation from any effect of the food. Itis obvious that consumption of less than 50% of the de-
livered product (and especially for products containing
IPB) would be a critical limitation and seriously com-
promise the final goal of the supplementation if this was
sustained over the longer term.
Additionally it could be emphasised from the data ob-
tained in this study that in cases where a practitioner
wishes to supplement a feline patient with not only IPB,
but also with a uremic toxin binder and eventually with
a supplement to help maintain normal kidney architec-
ture with the presentations which are currently available
on the market he/she will face the necessity to adminis-
ter three different formulations each with a rather low
inherent palatability. This low palatability may com-
promise compliance with supplement use in patients
and owners and may help explain the very poor market
penetration of CKD supplements [22,23]. For the prod-
ucts containing IPB, the lack of palatability could be eas-
ily explained by the nature of IPB, which are known to
have a lack of smell and taste: mostly they are simple
molecular entities or polymeric structures able to form
insoluble compounds with digestible phosphorus. Lack
of smell could be easily justified to human patients by
medical necessity, but it is not the case for animals.
Thus, for the manufacturers of supplements designed
for CKD animals and especially for cats, palatability
should be one of the highest priorities unless the prod-
uct is designed only for use when mixed with highly pal-
atable food.
The best performing product of the four currently on
the market was Azodyl®. One key point to note about
this study was that the capsules of Azodyl® were opened
and the contents applied to the food, while the manufac-
turer’s recommendation is to administer it as an entire
capsule. It is extremely rare for cats to voluntarily con-
sume a capsule without any forced administration. How-
ever, although not all owners are able or willing to
forcibly administer products to their cats, for those who
are experienced, direct administration of a capsule guar-
antees that the entire dose is received by the animal. It is
probable that the technique we used is relatively wide-
spread in the field.
The results of this study suggest that the galenic form of
the supplements could be an important factor. Rubenal® is
presented as a tablet, where, once again, if the owner is ex-
perienced enough, forced administration could ensure that
the complete dose was received on each occasion. However
not all cats are amenable to this. The refusal of the product
by the majority of the cats may be linked to the absence of
a specific palatability agent and the large size of the tablet
(approximately 15 mm). It could have been possible to try
to crush the tablet to form a powder, and it may have been
interesting to have observed whether this may have reduced
the proportion of cats which totally refused to consume the
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able food may have had an impact on the results with this
product.
It could be speculated that in some cases even food in-
gestion could be compromised if unpalatable supplements
are added to the food, given the specificity of cats regarding
feeding [24]. Additionally, some reports have shown a li-
quid form, compared to tablets and capsules, could be
more efficient for intestinal binders [5] without taking into
account the amount of the supplement ingested. Finally,
given the frequent appetite problems in CKD animals and
especially in cats, supplements for renal disease should
allow the owner, in cases of necessity, to force the adminis-
tration. Anorexia in cats with chronic kidney disease is
often related to the intensity of uraemia and acidosis [5].
Administration of medication and appropriate supplements
regularly may allow decreased absorption of dietary phos-
phorus, thus preventing or decreasing hyperphosphatemia
and secondary hyperparathyroidism, and may even eventu-
ally attenuate uraemia [6] and related clinical signs to help
avoid malnutrition and weight loss in feline patients. In this
case if the palatability of the product is acceptable, the ani-
mal may be willing to ingest it by itself thus avoiding life-
time forced administration and facilitating ease of use for
the owner. However having a palatable presentation in a
form that also allows forced administration where necessary
could be the ideal situation. In the present study the only
supplement shown to have an acceptable level of palatabil-
ity was Pronefra®.Conclusion
One product in this study (Pronefra®) was clearly demon-
strated to have a higher prehension and consumption rate.
This could potentially help change the image of feline CKD
supplements which are perceived as products with low pal-
atability and instead allow the practitioner to propose early
nutritional intervention with multiple benefits and a high
chance of spontaneous intake in feline patients suffering
from chronic renal disease.Competing interests
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